Victoza
(Liraglutide)ApprovedPeptide
Novo NordiskLiraglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used to help with weight loss in people who are overweight or obese.[2] Victoza is currently approved and in use across 47 indications[4].[1]
Victoza is one of 830 small molecule programs targeting Obesity. It is currently in Approved.
47
Indications
371
Total Trials
9
Active Trials
829
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 46 indications
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Cagrisema
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes47 trials
Show 44 more trials
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
Completed·—·Phase 2·NCT01399645·35 enrolled
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04146155·200 enrolled
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
Unknown status·—·Phase 2·NCT03426085·44 enrolled
Liraglutide33 trials
Show 30 more trials
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
Withdrawn·—·Phase 4·NCT02198209
Obesity12 trials
Show 9 more trials
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT07374445·100 enrolled
Type 2 Diabetes Mellitus12 trials
Show 9 more trials
Weight loss11 trials
Show 8 more trials
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Not yet recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·NCT07301437·120 enrolled
Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg
Completed·—·N/A·NCT03534310·75 enrolled
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
Unknown status·GGeneral Committee of Teaching Hospitals and Institutes, Egypt·N/A·NCT05285397·60 enrolled
59 more indications
Type 1 Diabetes8 trials
Show 5 more trials
Osteoarthritis5 trials
Overweight3 trials
Obese Patients3 trials
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04325581·16 enrolled
GLP-13 trials
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT02501850·40 enrolled
Weight Management3 trials
Polycystic Ovary Syndrome2 trials
Binge Eating2 trials
Type 2 Diabetic Patients2 trials
Effectiveness2 trials
Gastric Emptying1 trial
AIN1 trial
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
Unknown status·—·Phase 4·NCT02055014·72 enrolled
Double-blind1 trial
Fatty Liver1 trial
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Terminated·—·Phase 4·NCT02721888·127 enrolled
Safety and Efficacy1 trial
Cardiovascular Disease1 trial
Infertility1 trial
Gestational Diabetes1 trial
Obstructive Sleep Apnea1 trial
Diabetic Neuropathy1 trial
Treatment of Diabetic Neuropathy With Liraglutide
Completed·—·N/A·NCT02138045·39 enrolled
Efficacy and Safety1 trial
Congestive Heart Failure1 trial
Ischemic Cardiomyopathy1 trial
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
Unknown status·—·N/A·NCT02930265·400 enrolled
Diabetes1 trial
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
Completed·—··NCT05162183·3,474 enrolled
Postmenopausal Women1 trial
Maturity-Onset Diabetes of the Young1 trial
Diabetes Mellitus1 trial
Local1 trial
Gastroesophageal Reflux1 trial
Heart Failure1 trial
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
Completed·—·Phase 2·NCT01800968·300 enrolled
PreDiabetes1 trial
Treatment1 trial
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Completed·—·Phase 3·NCT01937598·16 enrolled
Injury1 trial
Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury
Unknown status·—·N/A·NCT02001363·90 enrolled
Delirium1 trial
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT06361238·260 enrolled
Adverse Events1 trial
Endothelial Dysfunction1 trial
Trial1 trial
Bipolar Disorder1 trial
Concentration1 trial
Unspecified4 trials
Effects of GH and Lirglutide on AgRP
Recruiting·—·Phase 4·NCT05681299·40 enrolled
Antidiabetic Effects on Intrahepatic Fat
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT03068065·87 enrolled
Effects of Glucagon Like Peptide-1 on No-reflow
Unknown status·—·N/A·NCT02507128·190 enrolled
Show 1 more trial
Regulatory
FDA Approval Timeline[5]
Jan 25, 2010
VICTOZA
NDA NDA022341
Dec 23, 2014
SAXENDA
NDA NDA206321
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Victoza drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Liraglutide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucagon-Like Peptide 1 Receptor Agonist[3]
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Jan 9, 2037
Earliest patent expiration — generic entry possible after this date